3,535
Views
46
CrossRef citations to date
0
Altmetric
Research Article

Hybrid imidazole (benzimidazole)/pyridine (quinoline) derivatives and evaluation of their anticancer and antimycobacterial activity

, , , &
Pages 96-103 | Received 17 Mar 2016, Accepted 08 May 2016, Published online: 02 Jun 2016

References

  • Pozharskii AF, Soldatenkov AT, Katritzky AR. Heterocycles in life and society: an introduction to heterocyclic chemistry, biochemistry and applications. 2nd ed. Chichester: John Wiley & Sons; 2011
  • Grahman PL. An introduction to medicinal chemistry. 2nd ed. Oxford: Oxford University Press; 2001
  • Silverman RB, The organic chemistry of drug design and drug action. London: Academic Press; 1992
  • a. World Health Organization Tuberculosis Programme. Available from: Global tuberculosis report 2015/WHO/ http://www.who.int/tb/publications/global_report/en/ [last accessed 19 Feb 2016]. b. http://www.who.int/mediacentre/factsheets/fs297/en/ [last accessed 19 Feb 2016]
  • Rescifina A, Zagni C, Varrica MG, et al. Recent advances in small organic molecules as DNA intercalating agents: synthesis, activity, and modeling. Eur J Med Chem 2014;74:95–115
  • Xiang P, Zhou T, Wang L, et al. Novel benzothiazole, benzimidazolee and benzoxazole derivatives as potential antitumor agents: synthesis and preliminary in vitro biological evaluation. Molecules 2012;17:873–83
  • Wissner A, Mansour TS. The development of HKI-272 and related compounds for the treatment of cancer. Arch Pharm 2008;341:465–77
  • Denny WA. DNA minor groove alkylating agents. Curr Med Chem 2001;8:533–44
  • Zbancioc AM, Zbancioc G, Tanase C, et al. Design, synthesis and in vitro anticancer activity of a new class of bifunctional DNA intercalators. Lett Drug Des Discov 2010;7:644–9
  • Luca MC, Tura V, Mangalagiu II. Considerations concerning design and mechanism of action of a new class of anticancer dual DNA intercalators. Med Hypotheses 2010;75:627–9
  • Koseki Y, Kinjo T, Kobayashi M, Aoki S. Identification of novel antimycobacterial chemical agents through the in silico multi-conformational structure-based drug screening of a large-scale chemical library. Eur J Med Chem 2013;60:333–9
  • Gising J, Nilsson MT, Odell LR, et al. Trisubstituted imidazoles as Mycobacterium tuberculosis glutamine synthetase inhibitors. J Med Chem 2012;55:2894–8
  • Villemagne B, Crauste C, Flipo M, et al. Tuberculosis: the drug development pipeline at a glance. Eur J Med Chem 2012;51:1–16
  • Pandey J, Tiwari VK, Verma SS, et al. Synthesis and antitubercular screening of imidazole derivatives. Eur J Med Chem 2009;44:3350–5
  • Danac R, Managalagiu II. Antimycobacterial activity of nitrogen heterocycles derivatives: bipyridine derivatives. Part III. Eur J Med Chem 2014;74:664–70
  • Danac R, Al Matarneh C, Shova S, et al. New indolizines with phenanthroline skeleton: synthesis, structure, antimycobacterial and anticancer properties. Bioorgan Med Chem 2015;23:2318–27
  • Al Matarneh C, Mangalagiu II, Shova S, Danac R. Synthesis, structure, antimycobacterial and anticancer evaluation of new pyrrolo-phenanthroline derivatives. J Enzym Inh Med Chem 2015;31:470–80
  • Antoci V, Mantu D, Cozma DG, et al. Hybrid anticancer 1,2-diazine derivatives with multiple mechanism of action. Part 3. Med Hypotheses 2014;82:11–15
  • Balan AM, Miron A, Tuchilus C, et al. Synthesis and in vitro analysis of novel dihydroxyacetophenone derivatives with antimicrobial and antitumor activities. Med Chem 2014;10:476–83
  • Danac R, Daniloaia T, Antoci V, Mangalagiu II. Design, synthesis and antimycobacterial activity of some new azaheterocycles: phenanthroline with p-halogeno-benzoyl skeleton. Part V. Lett Drug Des Discov 2015;12:14–19
  • Mantu D, Antoci V, Mangalagiu II. Design, synthesis and antimycobacterial activity of some new pyridazine derivatives: bis-pyridazine. Part IV. Infect Disord Drug Targets 2013;13:344–51
  • Mantu D, Luca C, Moldoveanu C, et al. Synthesis and antituberculosis activity of some new pyridazine derivatives. Part II. Eur J Med Chem 2010;45:5164–8
  • Moldoveanu C, Mangalagiu G, Drochioiu G, et al. New antituberculosis compounds derived from diazine. An Stiint Univ “Al.I.Cuza” Iasi 2003;11:367–74. [Chem. Abstr. 142 (2004) 56249]
  • Ma L, Li S, Zheng H, et al. Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease. Eur J Med Chem 2011;46:2003–10
  • Zhou X, Yan W, Zhao T, et al. Rhodamine based derivative and its zinc complex: synthesis and recognition behavior toward Hg(II). Tetrahedron 2013;69:9535–9
  • US National Cancer Institute (NCI). 2016. Bethesda. Available from: http://dtp.nci.nih.gov/ [last accessed 19 Feb 2016]
  • Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813–23
  • Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen utilizing a diverse panel of human tumour cell lines in culture. J Natl Cancer Inst 1991;83:757–66
  • Boyd RM, Paull KD. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Develop Res 1995;34:91–109
  • Bevan CD, Lloyd RS. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal Chem 2000;72:1781–7
  • Carroll P, Schreuder LJ, Muwanguzi-Karugaba J, et al. Sensitive detection of gene expression in Mycobacteria under replicating and non-replicating conditions using optimized far-red reporters. PLoS One 2010;5:e9823
  • Ollinger J, Bailey MA, Moraski GC, et al. A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis. PLoS One 2013;8:e60531
  • Zelmer A, Carroll P, Andreu N, et al. A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging. J Antimicrob Chemother 2012;67:1948–60
  • Lambert RJ, Pearson J. Susceptibility testing: accurate and reproducible minimum inhibitory concentration (MIC) and non-inhibitory concentration (NIC) values. J Appl Microbiol 2000;88:784–90

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.